Appili Therapeutics Inc. (TSX:APLI)

Revenue by Segment

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Biotechnology (Startups)	100.44K	827.41K	334.18K	1.39M		199.11K
Biotechnology (Startups) Growth	-87.86%	147.60%	-75.97%	-		-
Total	100.44K	827.41K	334.18K	1.39M		199.11K
Total Growth	-87.86%	147.60%	-75.97%	-		-

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Canada	100.44K	827.41K	334.18K	1.39M		199.11K
Canada Growth	-87.86%	147.60%	-75.97%	-		-
Total	100.44K	827.41K	334.18K	1.39M		199.11K
Total Growth	-87.86%	147.60%	-75.97%	-		-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error